Cargando…

Preclinical Evidence of STAT3 Inhibitor Pacritinib Overcoming Temozolomide Resistance via Downregulating miR-21-Enriched Exosomes from M2 Glioblastoma-Associated Macrophages

Background: The tumor microenvironment (TME) plays a crucial role in virtually every aspect of tumorigenesis of glioblastoma multiforme (GBM). A dysfunctional TME promotes drug resistance, disease recurrence, and distant metastasis. Recent evidence indicates that exosomes released by stromal cells w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chuang, Hao-Yu, Su, Yu-kai, Liu, Heng-Wei, Chen, Chao-Hsuan, Chiu, Shao-Chih, Cho, Der-Yang, Lin, Shinn-Zong, Chen, Yueh-Sheng, Lin, Chien-Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678764/ https://www.ncbi.nlm.nih.gov/pubmed/31269723 http://dx.doi.org/10.3390/jcm8070959

Ejemplares similares

The odyssey of pacritinib in myelofibrosis
por: Venugopal, Sangeetha, et al.
Publicado: (2022)

Emerging treatment options for myelofibrosis: focus on pacritinib
por: Chow, Vivian, et al.
Publicado: (2016)

Potential Strategies Overcoming the Temozolomide Resistance for Glioblastoma
por: JIAPAER, Shabierjiang, et al.
Publicado: (2018)

The JAK2/STAT3 inhibitor pacritinib effectively inhibits patient-derived GBM brain tumor initiating cells in vitro and when used in combination with temozolomide increases survival in an orthotopic xenograft model
por: Jensen, Katharine Victoria, et al.
Publicado: (2017)

Profile of pacritinib and its potential in the treatment of hematologic disorders
por: Hatzimichael, Eleftheria, et al.
Publicado: (2014)

Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia
por: Verstovsek, Srdan, et al.
Publicado: (2021)

HOXD‐AS2‐STAT3 feedback loop attenuates sensitivity to temozolomide in glioblastoma
por: Zhang, Zuo‐Xin, et al.
Publicado: (2023)

Evaluation of Temozolomide and Fingolimod Treatments in Glioblastoma Preclinical Models
por: Davy, Mélodie, et al.
Publicado: (2023)

Nanomedicine-based combination therapies for overcoming temozolomide resistance in glioblastomas
por: Wang, Chun, et al.
Publicado: (2023)

The oral HDAC inhibitor pracinostat (SB939) is efficacious and synergistic with the JAK2 inhibitor pacritinib (SB1518) in preclinical models of AML
por: Novotny-Diermayr, V, et al.
Publicado: (2012)

Resveratrol Enhances Temozolomide Efficacy in Glioblastoma Cells through Downregulated MGMT and Negative Regulators-Related STAT3 Inactivation
por: Wu, Moli, et al.
Publicado: (2023)

Enrichment of superoxide dismutase 2 in glioblastoma confers to acquisition of temozolomide resistance that is associated with tumor-initiating cell subsets
por: Chien, Chia-Hung, et al.
Publicado: (2019)

NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition
por: Tsai, Cheng-Yu, et al.
Publicado: (2021)

P1068: RISK-ADJUSTED SAFETY ANALYSIS OF PACRITINIB IN PATIENTS WITH MYELOFIBROSIS
por: Vannucchi, A., et al.
Publicado: (2022)

Targeting BC200/miR218-5p Signaling Axis for Overcoming Temozolomide Resistance and Suppressing Glioma Stemness
por: Su, Yu-Kai, et al.
Publicado: (2020)

Inhibition of Carbonic Anhydrase 2 Overcomes Temozolomide Resistance in Glioblastoma Cells
por: Zhao, Kai, et al.
Publicado: (2021)

Inhibition of DNA Repair in Combination with Temozolomide or Dianhydrogalactiol Overcomes Temozolomide-Resistant Glioma Cells
por: Ohba, Shigeo, et al.
Publicado: (2021)

Comprehensive kinase profile of pacritinib, a nonmyelosuppressive Janus kinase 2 inhibitor
por: Singer, Jack W, et al.
Publicado: (2016)

Pacritinib abrogates the lupus phenotype in ABIN1[D485N] mice
por: Petrova, Tsvetana, et al.
Publicado: (2023)

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis
por: Torres, Sandra, et al.
Publicado: (2023)

Long-Term Hematologic Improvement in a Patient With Cytopenic Myelofibrosis Treated With Pacritinib
por: Yacoub, Abdulraheem, et al.
Publicado: (2023)

Pacritinib inhibits glucose consumption in squamous cell lung cancer cells by targeting FLT3
por: Ghezzi, Chiara, et al.
Publicado: (2023)

Metformin and temozolomide, a synergic option to overcome resistance in glioblastoma multiforme models
por: Valtorta, Silvia, et al.
Publicado: (2017)

Exosomal transfer of miR-1238 contributes to temozolomide-resistance in glioblastoma
por: Yin, Jianxing, et al.
Publicado: (2019)

Long-term treatment with pacritinib on a compassionate use basis in patients with advanced myelofibrosis
por: Harrison, Claire, et al.
Publicado: (2023)

Pacritinib is a potent ACVR1 inhibitor with significant anemia benefit in patients with myelofibrosis
por: Oh, Stephen T., et al.
Publicado: (2023)

P1037: CONSISTENCY OF PACRITINIB FOR SPLEEN AND SYMPTOM REDUCTION IN PATIENTS WITH MYELOFIBROSIS REGARDLESS OF CYTOPENIAS
por: Gagelmann, Nico, et al.
Publicado: (2023)

Complex DNA repair pathways as possible therapeutic targets to overcome temozolomide resistance in glioblastoma
por: Yoshimoto, Koji, et al.
Publicado: (2012)

MV1035 Overcomes Temozolomide Resistance in Patient-Derived Glioblastoma Stem Cell Lines
por: Malacrida, Alessio, et al.
Publicado: (2022)

Exploring the Mechanism of Adjuvant Treatment of Glioblastoma Using Temozolomide and Metformin
por: Feng, Shao-Wei, et al.
Publicado: (2022)

In search of effective therapies to overcome resistance to Temozolomide in brain tumours
por: Bouzinab, Kaouthar, et al.
Publicado: (2019)

Pilot study of the antifibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis
por: Al-Fayoumi, Suliman, et al.
Publicado: (2018)

P1069: RETROSPECTIVE COMPARISON OF PATIENT OUTCOMES ON PACRITINIB VERSUS RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS AND THROMBOCYTOPENIA
por: Harrison, C., et al.
Publicado: (2022)

Focused Ultrasound-Induced Blood–Brain Barrier Opening to Enhance Temozolomide Delivery for Glioblastoma Treatment: A Preclinical Study
por: Wei, Kuo-Chen, et al.
Publicado: (2013)

Exosomal connexin 43 regulates the resistance of glioma cells to temozolomide
por: Yang, Zhang-Jian, et al.
Publicado: (2021)

Exosomes and Stem Cells in Degenerative Disease Diagnosis and Therapy
por: Chang, Yu-Hsun, et al.
Publicado: (2018)

Downregulation of MGMT expression by targeted editing of DNA methylation enhances temozolomide sensitivity in glioblastoma
por: Han, Xinyu, et al.
Publicado: (2023)

Identification of MGMT Downregulation Induced by miRNA in Glioblastoma and Possible Effect on Temozolomide Sensitivity
por: Cardia, Andrea, et al.
Publicado: (2023)

Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia
por: Hart, S, et al.
Publicado: (2011)

Risk‐adjusted safety analysis of the oral JAK2/IRAK1 inhibitor pacritinib in patients with myelofibrosis
por: Pemmaraju, Naveen, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3eu9poq7b3545kdimaa284tkbt